Investigation Opened on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Shareholders - Contact Levi & Korsinsky

Core Insights - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies for setrusumab (UX143) in Osteogenesis Imperfecta [1][2] - The studies did not meet their primary endpoints, leading to a significant drop in Ultragenyx's stock price [2][3] Group 1: Study Results - The Phase III Orbit and Cosmic studies failed to achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates, respectively [2] - Although secondary endpoints showed improvements in bone material density, these did not correlate with a statistically significant reduction in fractures [2] Group 2: Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $14.87, a decrease of 43.49%, opening at $19.32 per share [3] - This decline has resulted in the stock reaching a new 52-week low, significantly below the previous low of $25.81 [3] Group 3: Company Response - Ultragenyx has indicated that it will implement significant expense reductions in response to the study outcomes [3]